RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures.  As part of this advancement, Inspira will deploy the ...

Core Insights - The company has achieved a significant milestone by generating initial revenues from its FDA-cleared life support technology, specifically the INSPIRA™ ART100 systems, deployed in a leading U.S. healthcare facility [1][2][3] - The revenue generated is in the low hundreds of thousands of dollars, marking a successful step in the company's strategy to expand its presence in the U.S. healthcare market [2][3] - The CEO emphasized that this achievement validates the company's innovative technology and its ability to collaborate with top-tier medical institutions, which is crucial for advancing the adoption of its life-support systems [3] Company Overview - Inspira Technologies is focused on developing innovative respiratory support and diagnostic technologies, with its flagship product, the INSPIRA ART500 system, designed to allow patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation [4] - The INSPIRA ART100 system is FDA-cleared for cardiopulmonary bypass procedures and has also received regulatory approvals in Israel for similar applications [4] - The company is also developing the HYLA blood sensor technology for continuous, real-time blood monitoring without the need for blood draws, along with other pipeline products [4] Market Context - The INSPIRA ART500 aims to revolutionize the $19 billion mechanical ventilation market by providing a safer alternative that allows patients to avoid mechanical ventilation during treatment [3] - The company plans to install additional INSPIRA ART100 systems at a second leading academic medical center, further expanding its clinical footprint [2][3]

Inspira's innovative FDA-cleared INSPIRA™ ART100 system was successfully deployed at premier U.S. hospital, with systems in place for clinical use RA'ANANA, Israel, March 25, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has successfully completed the installation, training program and operational readiness for its INSPIRA ART100 system for cardiopulmonary bypa ...